13th Jul 2016 06:40
LONDON (Alliance News) - AstraZeneca PLC said Wednesday it has agreed a deal to resolve a patent litigation in the US with Sandoz Inc and affiliates, relating to Sandoz's generic fulvestrant product, for which Sandoz is seeking US approval.
AstraZeneca's US patents in question are due to expire in January 2021, with paediatric exclusivity continuing until July 2021.
On Tuesday, the US District Court for New Jersey entered a consent judgement filed by AstraZeneca and Sandoz, including an injunction preventing Sandoz from launching a generic fulvestrant product until March 25, 2019, or earlier in some circumstances.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca